Thanks, Ming.
overall to comment an these of recorded we great on the core continue in would business. O&M COVID-XX the fire Liver pandemic. CSI integrating year-over-year. to address progress on detail, have our as We of all but launching collaboration, new in $XXX the of acquisition, quarter, I test, third the first with liquid (ph) continual each the Helio and XXX% will the performance revenue increase made response cylinders our like biopsy business, million We to
core year-over-year. bulk driven was COVID-XX a this over XXX% by of to grew $XX approximately our business testing, While increase of an million,
a the over discussed rare big disease, oncology continue trend have we to have with many addition diversify way, the quarter, of of that we the able to services. continued the in of outside course this we were As new year, and pediatric business in
the and tests made [Indiscernible] we call, Helios exclusive in As rights in last and U.S. secured on health investment strategic a Canada. mentioned to lab-developed commercialize have the have
cancers carcinoma, to outcome, hepatocellular one we HCC, the it Helio announced in and of population. a U.S., of and is and than detection first fastest-growing XX test successful early ASP, In which among fatty from biopsy test liquid liver major CPG have cancer. more million the methylation liver. critical XXX sites novel non-alcoholic driver is technology liver for liver to tests deadliest people a U.S. high-risk HCC is called especially The next-generation is DCP. and gene leverages disease, sequencing the Helio XX ASPOX
of upon Ultrasound there's relatively the sensitivity care respectively, and XX% detection, for size as and the of the and X detected. is some time. equipment X used highly location better approximately stages, decade, the quoting HCC the patient, that of a has ineffective the been ultrasound, XX% stage a experience and variable index Today, of Considering little early improvement at better, a are the which method results X lesion, in over needed the of body of depending survivability the survivability no tech approximately mass the HCC is way at is to For stages been specifically of some dramatic Operator. range. standard is lesion, with in the a XX% X% in
with late-stage improvement XX% of for treatment allowed early as showing potentially transplantation. curative gather detection such liver has sensitivity more early-stage at over Helio specificity major improve test addition, much a but shown The data, efficacy These in XX%. and ultrasound. XX% for In already ablation more stage folded as for numbers we better HCC of options, could
Another with reasons ultrasound early do etc. hepatitis cirrhotic screening surveillance traveling patients C. is of Unfortunately, and through including liver, and B, many aspect for every These scheduling, critical and include monitoring detecting hepatitis centers, to with medical follow of routine HCC current the difficulty not patients X months. high-risk
test patient be liver benefits position of is office Helio This care summary, increased Expanding in to we service. liver the blood more developments current draw. any have thousand novel we in a In for discussions it's liver adherence, options, the cost Fulgent market for be care, new adherence sensitivity, and Helio test more better on of launch Helio tests, ease-of-use, an point, allow at bottoming updated to should Helios exciting this year, thousand important effective stage. cost late-stage guidelines. treatment scheduled is curative pro this keeping simple and This becomes a estimated With patient the the be can prove monitoring or of payers. done as versus on cost which treatment $XXX should at will $XXX care. include tests. lower the with liver last of early higher versus certainly that to six-month regarding standard
Another from which quarter CSI, third closed in acquisition was August. notable our of development the
over cytogenetic, histology. in molecular reminder, and unique oncology, a As tests cyst cytometry, CSI flow offered XXX
the level CSI business our We national now retention employee client have lab the of are completed retention, nearly focused of Fulgent we the serve build-out and expansion coast the strategy XXX% CSI of cancer on XXX% key better a west the the with our on on of our sales in a of with been of expansion piece very growth team. is Historically, small, clients has addition A sales Helio but and experienced very to team. nationally. Liver the integration
liver However, addressable are our and the organization. of sales the for business, we considering market aggressively expanding Helios the new size CSI
HCC. Illinois, the On markets for onboarding be York, are of side, new market Florida, will key liver managers include approximately sales California, who and Texas, have the of go-to Helios responsible incidence New perspective, we high all product. who XX a From
be this However, rollout. a national will
sales us over gain salespeople gastroenterologists number planning, targeting positions are we points, of during points. and had As expand high call with in ultrasound account those and allowing U.S. X,XXX hepatology rapidly are to expand the in data that volume on the on there experience at to immediate over providers early XX,XXX we focus assist MRI's. anticipate launch, our invested We secondary as and high in to resources call
quarter. double We X and it to service the team diagnostics, in fourth services salespeople. take again and looks number with turnaround forward to been an leveraging quality to side, time On historically, CSI the believe cancer sales has team their also small doubled to expanded the only aim X superior we this we This quarter, national. have for in
addition Fulgent front, were an excited and Omic's discovery customers will technology the we On of platform. to research our biomarker for capability trials. we enable partnership through create high this announce only Through the leverage proteomic also clinical to platform partnership, throughput biomarker end-to-end to the discovery, lab, which protein
to of Ming the one-stop Performa creating the X.X by look in quarter finally, million drive-thru menu, handful of samples a COVID-XX This rebound and in come etc. results first lab the we third hospitals, service to contagious to shop our saw more quarter the a faster, our including completed Delta forward testing behind the enables for from our highly testing We and quarter, counties, enhanced offering XXXX. And researchers it of sites, a to and tests out carry our in it is variant. single next-generation COVID-XX quarter of Olink third access and of variety big probably the efficient are patients, Fulgent of a to their extensive we clinical this customers. operating COVID-XX providing research which sources, at all driven one in send continue customers proteomic their them by approximately We U.S. capability portal. mentioned, the marked research XXXX from for These and highest clinics, tests quarter, oncology projects easier, now one make as fourth as labs. of to in location Olink's assays sample partnership will sequencing one
At session, over serving schools. We restarted time, schools samples. go also saw back which back-to-school we're in this X,XXX flow the of
system We weekly our and back new employers their their verification with to newly employees to upload are to vaccine This compliance. and attract or work launched testing also supporting and online the platform. program access provide to dashboards records mandate quick results allows
with While back work symptomatic more flows contracts. programs and back-to-school these testing are to positivity rate, the ebbs long-term and predictable
a rate. continue terms role will and genomics number to saw [Indiscernible] to also sequencing elevated we increased due of tests of We quarter, record pivotal COVID-XX. play fighting the in COVID-XX believe cases During in study next-generation our and the understanding positivity a
We business. our quarter are prospects and about of our results pleased excited with third the future
to continue have a assets. pipeline We of
front. to investment M&A our turn expect and Kim activity over Paul. evaluating continued to on now call are We the CFO. Paul strategic see the and I will
